Epigenomics AG, DE000A32VN83

Epigenomics AG / DE000A32VN83

30.10.2023 - 15:49:55

Epigenomics AG: Executive Board member Jens Ravens leaves the Company on April 30, 2024

EQS-Ad-hoc: Epigenomics AG / Key word(s): Personnel


30-Oct-2023 / 15:49 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


Berlin, Germany, October 30, 2023 – Jens Ravens, Executive Board member of Epigenomics AG (Frankfurt General Standard: ECX1, the “Company”), leaves the Executive Board of the Company with effect as of April 30, 2024, due to the successful transfer of nearly all assets of the Company to New Day Diagnostics LLC. The Supervisory Board will appoint a new Executive Board member in due course and decide on the further composition of the Executive Board.   Contact:
Company
Epigenomics AG, Bertha-Benz-Strasse 5, 10557 Berlin
Tel +49 (0) 30 24345 0, Fax +49 (0) 30 24345 555, Email: contact@epigenomics.com Investor Relations
IR.on AG, Frederic Hilke, Tel +49 221 9140 970, Email: ir@epigenomics.com
Note on forward-looking statements This publication expressly or implicitly contains forward-looking statements concerning Epigenomics AG and its business. These statements involve certain known and unknown risks, uncertainties and other factors that may cause Epigenomics AG's actual results, financial condition and performance to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Epigenomics makes this announcement as of the date of this release and does not intend to update any forward-looking statements contained herein as a result of new information or future events or otherwise.  


End of Inside Information

30-Oct-2023 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com

Language: English
Company: Epigenomics AG
Bertha-Benz-Straße 5
10557 Berlin
Germany
Phone: +49 30 24345-0
Fax: +49 30 24345-555
E-mail: ir@epigenomics.com
Internet: www.epigenomics.com
ISIN: DE000A32VN83
WKN: A32VN8
Listed: Regulated Market in Frankfurt (General Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 1760753

 
End of Announcement EQS News Service

1760753  30-Oct-2023 CET/CEST
fncls.ssp?fn=show_t_gif&application_id=1760753&application_name=news&site_id=trading-house
@ dgap.de